Literature DB >> 35118454

Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes.

Dimitrios G Chatzis1, Konstantinos Kolokathis2, Kalliopi Magounaki1, Stefanos Chatzidakis1, Konstantinos Avramidis2, Marianna Leopoulou3, Theodoros P Angelopoulos4, John Doupis2,4.   

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic disease with a constantly increasing prevalence worldwide. It is well established that T2DM affects both the macro- and microvasculature, and its presence is associated with a high risk of acute and chronic cardiovascular events. Traditionally, the management of T2DM has been mainly focused on the optimization of blood glucose levels with the use of antidiabetic medications. During recent years, however, an impressive accumulation of evidence has arisen from studies designed to explore the plausible effects of new antidiabetic drugs on cardiovascular outcomes in patients with diabetes. This review article aims to emphasize the findings of these studies and to highlight the substantial role of the newer classes of antidiabetic drugs in treating T2DM in a holistic, cardiorenal-metabolic approach, thus shifting the paradigm from the traditional, simplistic, glucose-lowering approach. © Touch Medical Media 2021.

Entities:  

Keywords:  Type 2 diabetes mellitus (T2DM); cardiorenal-metabolic; glucose-lowering; treatment

Year:  2021        PMID: 35118454      PMCID: PMC8676106          DOI: 10.17925/EE.2021.17.2.92

Source DB:  PubMed          Journal:  touchREV Endocrinol        ISSN: 2752-5457


  62 in total

1.  FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.

Authors:  Darren K McGuire; Nikolaus Marx; Odd Erik Johansen; Silvio E Inzucchi; Julio Rosenstock; Jyothis T George
Journal:  Diabetes Obes Metab       Date:  2019-03-12       Impact factor: 6.577

2.  Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Authors:  Julio Rosenstock; Vlado Perkovic; Odd Erik Johansen; Mark E Cooper; Steven E Kahn; Nikolaus Marx; John H Alexander; Michael Pencina; Robert D Toto; Christoph Wanner; Bernard Zinman; Hans Juergen Woerle; David Baanstra; Egon Pfarr; Sven Schnaidt; Thomas Meinicke; Jyothis T George; Maximilian von Eynatten; Darren K McGuire
Journal:  JAMA       Date:  2019-01-01       Impact factor: 56.272

Review 3.  Epidemiology in diabetes mellitus and cardiovascular disease.

Authors:  Wenjun Fan
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

4.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.

Authors:  Jacob A Udell; Deepak L Bhatt; Eugene Braunwald; Matthew A Cavender; Ofri Mosenzon; Ph Gabriel Steg; Jaime A Davidson; Jose C Nicolau; Ramon Corbalan; Boaz Hirshberg; Robert Frederich; KyungAh Im; Amarachi A Umez-Eronini; Ping He; Darren K McGuire; Lawrence A Leiter; Itamar Raz; Benjamin M Scirica
Journal:  Diabetes Care       Date:  2014-12-31       Impact factor: 19.112

5.  Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

Authors:  Faiez Zannad; Christopher P Cannon; William C Cushman; George L Bakris; Venu Menon; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; Hung Lam; William B White
Journal:  Lancet       Date:  2015-03-10       Impact factor: 79.321

6.  Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?

Authors:  Robert J Smith; Allison B Goldfine; William R Hiatt
Journal:  Diabetes Care       Date:  2016-05       Impact factor: 19.112

Review 7.  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

8.  Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Authors:  William T Cefalu; Sanjay Kaul; Hertzel C Gerstein; Rury R Holman; Bernard Zinman; Jay S Skyler; Jennifer B Green; John B Buse; Silvio E Inzucchi; Lawrence A Leiter; Itamar Raz; Julio Rosenstock; Matthew C Riddle
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

9.  Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.

Authors:  Oliver Schnell; Eberhard Standl; Doina Catrinoiu; Baruch Itzhak; Nebojsa Lalic; Dario Rahelic; Jan Skrha; Paul Valensi; Antonio Ceriello
Journal:  Cardiovasc Diabetol       Date:  2019-03-11       Impact factor: 9.951

Review 10.  GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.

Authors:  José Luis Górriz; María José Soler; Juan F Navarro-González; Clara García-Carro; María Jesús Puchades; Luis D'Marco; Alberto Martínez Castelao; Beatriz Fernández-Fernández; Alberto Ortiz; Carmen Górriz-Zambrano; Jorge Navarro-Pérez; Juan José Gorgojo-Martinez
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.